摘要
目的:探讨调强适形放疗同步化疗治疗宫颈癌术后患者的疗效及不良反应。方法:回顾分析2009年1月-2012年5月期间45例早期宫颈癌术后具有不良预后因素行放射治疗的患者资料。其中调强放疗组21例,常规组24例。放疗期间同步化疗,方案为顺铂(50mg/m2)联合多西他赛(60-75mg/m2)或紫杉醇(175mg/m2)。多西他赛或紫杉醇分d1、d8静滴,顺铂分d2、d9静滴,间隔2周,开始下一疗程。有2个以上淋巴结转移者术后化疗4-6个疗程,有其他高危因素者同步化疗3-4个疗程。结果:24例常规组中3例复发,21例IMRT治疗组中2例复发,放化疗中骨髓抑制、胃肠道反应及泌尿系反应两组均无统计学差异,但调强治疗组明显减少了III级不良反应的发生。结论:尽管统计未能显示不良反应及复发差异,但调强治疗组明显减少了II、III级不良反应的发生。
Objective：To investigate the curative effect and adverse reaction of intensity-modulated conformal radiotherapy synchronous chemotherapy to treat cerical cancer.Methods：To retrospectively analyze the data of 45 cases with post-operative cervical cancer with poor prognosis factors intensity-modulated radiotherapy group 21 cases,conventional group 24 cases.During radiotherapy synchronous chemotherapy,cisplatin （50mg/m2） combined with many west he ＂（60-75mg/m2） or paclitaxel （175mg/m2） ＂.Many west he＂ or paclitaxel d1,d8,cisplatin d2,d9＂.Results：Of 24 cases in the conventional group,3 cases were recurrence,21 cases of IMRT treatment group 2 cases were relapse.Bone marrow suppression,gastrointestinal reaction and urinary tract reaction two groups were not statistically different,but intensity-modulated treatment group significantly reduced level Ⅲ adverse events.Conclusion：Although there is no defference in adverse reaction and recurrence,intensity-modulated treatment group significantly reduced Ⅱ,Ⅲ adverse events.
出处
《现代肿瘤医学》
CAS
2013年第9期2070-2073,共4页
Journal of Modern Oncology
关键词
宫颈癌
同步化疗
调强放射治疗
cervical cancer
synchronous chemotherapy
intensity-modulated radiation therapy
